Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients

Migraine Disorders Clinical Trial

Official title:

Greater Occipital and Supraorbital Nerve Blockade For The Preventive Treatment of Migraine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03435185
• Other study ID #: 2014/514/85/5
• Status: Completed
• Phase: N/A
• Start date: September 1, 2014
• Est. completion date: June 1, 2016

Study information

• Verified date: March 2022
• Source: Dr. Lutfi Kirdar Kartal Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators aimed to evaluate the efficacy of greater occipital nerve and supraorbital nerve blockade with local anesthetics for the preventive treatment of migraine without aura.

Description:

A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to GON and SON in the blockade patients. Placebo patients received 2 ml 0.9% saline in the same way. Patients were blinded to kind of injection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 103
• Est. completion date: June 1, 2016
• Est. primary completion date: June 1, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Lack of benefits 1 year from preventive treatment or intolerance to their treatments.

• 18 = years old

• Migraine without aura for more than 1 year, minimum of two or more migraine attacks per month.

Exclusion Criteria:

• Patients with any chronic illness, medication overuse headache, a history of cranial and cervical surgery

• Allergies to local anesthetics

• Hemorrhagic diathesis

• Alcohol or drug abuse

Related Conditions & MeSH terms

• Migraine Disorders

Intervention

Procedure:
• Lidocaine injections
Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.
• Saline injections
Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Dr. Lutfi Kirdar Kartal Training and Research Hospital

References & Publications (1)

Tang Y, Kang J, Zhang Y, Zhang X. Influence of greater occipital nerve block on pain severity in migraine patients: A systematic review and meta-analysis. Am J Emerg Med. 2017 Nov;35(11):1750-1754. doi: 10.1016/j.ajem.2017.08.027. Epub 2017 Aug 14. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of Frequency of Headache	Number of headache days in a month. Scores from both months were averaged. Minimum=0 Maximum=30. Lower scores mean a better outcome.	Patients were followed up from baseline to 2 months after first injection.
Primary	Change of Severity of Headache	Mean visual analog scale (VAS) scores. Scores from both months were avareged. Minimum=0 Maximum=10. Lower scores mean a better outcome	Patients were followed up for 2 months from baseline after first injection.